Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Central Africa has been on the rise in recent years.
Customer preferences: Central Africa has a large population that suffers from various types of arthritis, which is a major driver of the demand for Anti-Rheumatic Drugs. Patients in Central Africa prefer to use generic drugs due to the high cost of branded drugs. This preference is driven by the low purchasing power of the population.
Trends in the market: The Anti-Rheumatic Drugs market in Central Africa has been growing steadily in recent years. The increasing prevalence of arthritis, coupled with the growing population, has led to a rise in demand for these drugs. The market is dominated by nonsteroidal anti-inflammatory drugs (NSAIDs), which are the most commonly used drugs to treat arthritis. However, there has been a shift towards the use of disease-modifying antirheumatic drugs (DMARDs), which are more effective in treating the underlying causes of arthritis.
Local special circumstances: The lack of access to healthcare facilities and trained medical professionals in Central Africa has led to a rise in self-medication among the population. This has resulted in an increase in the use of counterfeit drugs, which are often cheaper but are of poor quality and can cause serious health problems.
Underlying macroeconomic factors: Central Africa is a region with a low GDP per capita, which limits the purchasing power of the population. The region is also heavily reliant on imports for medicines, which makes it vulnerable to fluctuations in exchange rates. The lack of investment in the healthcare sector has also contributed to the high cost of healthcare services and drugs. The governments in the region have been working to improve access to healthcare facilities and reduce the cost of drugs, but progress has been slow due to limited resources.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
